Cargando…
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs
Monoclonal antibodies (MAbs) are among the fastest-growing therapeutics and are being developed for a broad range of indications, including the neutralization of toxins, bacteria and viruses. Nevertheless, MAbs potency is still relatively low when compared to conventional polyclonal Ab preparations....
Autores principales: | Diamant, Eran, Torgeman, Amram, Ozeri, Eyal, Zichel, Ran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488679/ https://www.ncbi.nlm.nih.gov/pubmed/26035486 http://dx.doi.org/10.3390/toxins7061854 |
Ejemplares similares
-
Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations
por: Torgeman, Amram, et al.
Publicado: (2017) -
Highly Specific Monoclonal Antibody Targeting the Botulinum Neurotoxin Type E Exposed SNAP-25 Neoepitope
por: Mechaly, Adva, et al.
Publicado: (2022) -
Small Molecule Receptor Binding Inhibitors with In Vivo Efficacy against Botulinum Neurotoxin Serotypes A and E
por: Ben David, Alon, et al.
Publicado: (2021) -
A Rabbit Model for the Evaluation of Drugs for Treating the Chronic Phase of Botulism
por: Torgeman, Amram, et al.
Publicado: (2021) -
Evaluating the Synergistic Neutralizing Effect of Anti-Botulinum Oligoclonal Antibody Preparations
por: Diamant, Eran, et al.
Publicado: (2014)